Valuation: Mesoblast Limited

Market Cap 3.15B 2.21B 1.94B 1.79B 1.65B 3.1B 213B 21.39B 8.39B 104B 8.29B 8.11B 359B P/E 2026 *
-39x
P/E 2027 * 86.2x
Enterprise Value 3.13B 2.19B 1.92B 1.78B 1.63B 3.08B 211B 21.24B 8.32B 103B 8.23B 8.05B 356B EV / Sales 2026 *
17.4x
EV / Sales 2027 * 9.78x
Free-Float
64%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Mesoblast Limited

1 day-4.53%
1 week-2.52%
Current month+18.67%
1 month+7.41%
3 months+0.87%
6 months-7.20%
Current year-14.71%
1 week 2.28
Extreme 2.28
2.78
1 month 1.88
Extreme 1.88
2.78
Current year 1.88
Extreme 1.88
3.31
1 year 1.88
Extreme 1.88
3.31
3 years 0.26
Extreme 0.255
3.37
5 years 0.26
Extreme 0.255
3.37
10 years 0.26
Extreme 0.255
5.7
Manager TitleAgeSince
Chief Executive Officer 69 2011-03-22
Director of Finance/CFO 59 2025-11-16
Chief Tech/Sci/R&D Officer - 2026-03-10
Director TitleAgeSince
Director/Board Member 69 2006-12-31
Director/Board Member 75 2013-04-14
Director/Board Member 78 2014-03-05
Date Insider Type Main position Quantity % Market Cap.
4/16/26 Buy

Director

700,000 0.0543%
4/16/26 Buy

Director

2,324,072 0.1801%
4/16/26 Buy

Director

4,886,890 0.3787%
Change 5-day change 1-year change 3-year change Capi.($)
-4.53%-2.52%+0.43%+69.96% 2.21B
-0.49%-4.01%-0.84%+2.28% 49.18B
-3.10%-1.94%+370.99%+572.60% 39.58B
-0.46%+2.18%+5.44%+61.01% 34.69B
-1.14%-1.76%+26.94%-9.93% 34.42B
-1.82%-1.43%+0.52%+31.85% 27.11B
-3.54%-5.08% - - 16.21B
-1.82%-0.43%+69.28%+113.82% 15.36B
+1.17%+2.30%+15.87%+18.26% 14.05B
-2.25%+0.05%+15.77%-32.83% 13.02B
Average -1.80%-0.77%+56.04%+91.89% 24.58B
Weighted average by Cap. -1.46%-1.01%+75.19%+118.21%

Financials

2026 *2027 *
Net sales 180M 126M 111M 102M 94.01M 177M 12.17B 1.22B 479M 5.95B 474M 463M 20.51B 311M 218M 191M 177M 162M 306M 21.01B 2.11B 827M 10.28B 818M 800M 35.42B
Net income -76.81M -53.77M -47.13M -43.56M -40.06M -75.59M -5.18B -521M -204M -2.54B -202M -197M -8.74B 47.76M 33.44M 29.31M 27.09M 24.91M 47.01M 3.22B 324M 127M 1.58B 126M 123M 5.44B
Net Debt -23.05M -16.13M -14.14M -13.07M -12.02M -22.68M -1.56B -156M -61.27M -761M -60.58M -59.26M -2.62B -110M -76.67M -67.2M -62.11M -57.13M -108M -7.39B -743M -291M -3.62B -288M -282M -12.46B
Logo Mesoblast Limited
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Employees
81
Date Price Change Volume
26-07-20 A$2.320 -4.53% 970,386
26-07-20 A$2.430 -0.41% 2,409,244
26-07-17 A$2.440 -11.91% 7,134,866
26-07-16 A$2.770 +6.95% 7,786,526
26-07-15 A$2.590 +8.82% 6,562,425
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.430AUD
Average target price
3.798AUD
Spread / Average Target
+56.28%

Quarterly revenue - Rate of surprise